Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer's Hemophilia A Portfolio Boosted by Jivi's EU Approval

Executive Summary

EU approval and coming launch there of Jivi will complement Bayer's two existing Factor VIII treatments, Kogenate and its successor Kovaltry.

Advertisement

Related Content

Analysts Weigh Up Benefits Of Big Bayer Restructuring
Big Changes At Bayer With Animal Health Exit And 12,000 Jobs Cut
Roche's Hemlibra Wins Expanded FDA Approval, Opening The Door To Broad Hemophilia A Opportunity
Bayer To Ship Long-Acting Hemophilia Infusion Jivi In A Jiffy
Hemophilia Gene Therapy Studies Could Use Non-Inferiority Design, US FDA Suggests
BioMarin, Spark Hemophilia Gene Therapies Progress As Accelerated Approval Favors Their Indications
Sanofi Builds Blood Disorder Specialty With Bioverativ Buy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124245

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel